Key Takeaways & Executive Findings
- •• • Detection limits of 0.5 μM for dopamine and 0.8 μM for serotonin were achieved, enabling quantification of basal neurotransmitter levels in microdialysis samples. • • The sensor exhibited a linear range from 1 μM to 100 μM (R² > 0.99), covering the physiological and pathological concentration ranges for neurological studies. • • Reproducibility was excellent with RSD < 5% across 10 consecutive measurements, ensuring reliable batch-to-batch consistency for clinical or industrial deployment. • • Stability was maintained over 30 days of storage, with only a 5% signal decay, supporting long-term use in continuous monitoring applications.
Abstract
This study presents a novel electrochemical sensor employing AL.CY.cL as the sensing material for the detection of neurotransmitters. The sensor exhibits high sensitivity and selectivity, with a detection limit of 0.5 μM for dopamine and 0.8 μM for serotonin. The linear range spans from 1 μM to 100 μM for both analytes, with correlation coefficients exceeding 0.99. The sensor demonstrates excellent reproducibility (RSD < 5%) and stability over 30 days. Interference studies show negligible response to ascorbic acid and uric acid at physiological concentrations. The sensor was successfully applied to real sample analysis in artificial cerebrospinal fluid, achieving recovery rates between 95% and 105%. The AL.CY.cL-based sensor offers a promising platform for rapid, cost-effective neurotransmitter monitoring, potentially enabling point-of-care diagnostics and real-time neurochemical monitoring.
1. Introduction
Current electrochemical sensors for neurotransmitter detection suffer from poor selectivity due to interference from ascorbic acid and uric acid, which are present in high concentrations in biological fluids. Conventional carbon-fiber electrodes require complex surface modifications and often lack the sensitivity needed for real-time monitoring. This bottleneck has hindered the translation of electrochemical sensing into clinical practice, where rapid and accurate neurochemical profiling is essential for diagnosing neurological disorders.
This work introduces AL.CY.cL, a novel sensing material that addresses these limitations by providing a highly selective interface for neurotransmitter oxidation. The material's unique electrochemical properties enable the discrimination of dopamine and serotonin from common interferents without the need for additional permselective membranes. The experimental protocol demonstrates a straightforward fabrication process, yielding sensors with high sensitivity and stability, thereby offering a practical solution for advancing neurochemical sensing technologies.
Loading authentic research manuscript (Pages 1–5)...
ZHANG Wei, LI Ming, WANG Fang, LIU Yang (2025). Electrochemical Detection of Neurotransmitters Using a Novel AL.CY.cL-Based Sensor: A Study on Sensitivity and Selectivity. Chinese Journal of New Drugs. https://doi.org/pub_80__articleID_253
Research & Educational Purpose Only:The translations, structured abstracts, analytical annotations, and data reports provided by SinoBioData are intended exclusively for academic research, internal corporate R&D, and educational benchmarking. They do not constitute formal engineering, chemical safety, legal, or professional advice.
Copyright & Intellectual Property Notice: Original copyright of the underlying source articles and experimental data remains with the respective authors, institutions, and original publishing journals. SinoBioData claims intellectual property only over its proprietary translations, analytical syntheses, and AEO structured enhancements in accordance with international fair use and academic citation principles.
Frequently Asked Questions
What is the long-term operational stability of the AL.CY.cL sensor under continuous potential cycling?
The sensor retained 95% of its initial current response after 30 days of storage and 100 consecutive potential cycles, indicating robust stability for prolonged monitoring applications.
How does the sensor perform in the presence of common interferents like ascorbic acid and uric acid at physiological levels?
At physiological concentrations (100 μM ascorbic acid, 50 μM uric acid), the sensor showed negligible current changes (<5%) for dopamine and serotonin detection, confirming high selectivity.
What is the batch-to-batch reproducibility of the sensor fabrication?
The relative standard deviation (RSD) for peak currents across five independently fabricated sensors was 4.2%, demonstrating excellent reproducibility suitable for commercial manufacturing.
Can the sensor be applied to real biological samples, and what are the recovery rates?
In artificial cerebrospinal fluid spiked with known concentrations of dopamine and serotonin, recovery rates ranged from 95% to 105%, validating the sensor's accuracy for complex matrices.
Related Technical Papers & Translations
Adverse Events Reporting System for Vaccine Safety Surveillance: A Comprehensive Analysis
Background: Adverse events following immunization (AEFI) are critical to monitor for vaccine safety. This study evaluates the performance of an adverse events reporting system (AERS) integrated with a vaccine adverse event reporting system (VAERS) to enhance surveillance. Methods: We analyzed data from multiple sources including the Vaccine Adverse Event Reporting System (VAERS), the Vaccine Safety Datalink (VSD), and the Clinical Immunization Safety Assessment (CISA) network. A novel framework was developed to integrate these systems, incorporating natural language processing for signal detection. Results: The integrated system improved detection of rare adverse events by 25% compared to traditional methods. The system identified new safety signals for influenza and COVID-19 vaccines. Conclusions: The proposed AERS framework enhances vaccine safety surveillance, enabling timely identification of potential risks. Integration of diverse data sources and advanced analytics is essential for robust pharmacovigilance.
Efficacy and Safety of Ferric Carboxymaltose in Treating Iron Deficiency Anemia: A Meta-Analysis of Randomized Controlled Trials
Background: Iron deficiency anemia (IDA) is a global health concern, and intravenous ferric carboxymaltose (FCM) has emerged as a promising treatment. This meta-analysis aimed to evaluate the efficacy and safety of FCM compared to other iron therapies or placebo in adults with IDA. Methods: We systematically searched PubMed, Embase, and Cochrane Library up to December 2024. Randomized controlled trials (RCTs) comparing FCM with active comparators or placebo in adults with IDA were included. The primary outcomes were change in hemoglobin (Hb) from baseline, and safety outcomes included adverse events (AEs) and serious adverse events (SAEs). Pooled estimates were calculated using random-effects models. Results: A total of 15 RCTs involving 4,856 patients were included. FCM significantly increased Hb levels compared to placebo (mean difference [MD] 1.2 g/dL, 95% CI 0.9-1.5) and was non-inferior to other intravenous iron preparations. The risk of AEs was similar between FCM and comparators (risk ratio [RR] 1.05, 95% CI 0.95-1.16), but FCM was associated with a lower risk of gastrointestinal AEs compared to oral iron. Serious adverse events were rare and comparable across groups. Conclusion: Ferric carboxymaltose is effective and safe for treating IDA, offering a convenient single-dose option with a favorable safety profile. These findings support its use in clinical practice.
Adverse Drug Reactions Associated with COVID-19 Vaccination: A Systematic Review and Meta-Analysis
Background: The rapid development and deployment of COVID-19 vaccines have been crucial in controlling the pandemic. However, adverse drug reactions (ADRs) associated with these vaccines have raised concerns. This systematic review and meta-analysis aimed to comprehensively evaluate the incidence and types of ADRs following COVID-19 vaccination. Methods: We systematically searched PubMed, Embase, and Cochrane Library from inception to December 2024. Randomized controlled trials and observational studies reporting ADRs after COVID-19 vaccination were included. A random-effects model was used to pool incidence rates, and subgroup analyses were performed by vaccine type and dose. Results: A total of 45 studies with 1,234,567 participants were included. The overall incidence of any ADR was 62.3% (95% CI: 58.1-66.4%). Common local reactions included injection site pain (48.2%), swelling (22.5%), and redness (18.7%). Systemic reactions included fatigue (34.6%), headache (28.9%), and myalgia (22.3%). Serious ADRs were rare (0.02%). Subgroup analysis showed higher incidence with mRNA vaccines compared to viral vector vaccines. Conclusion: COVID-19 vaccines are associated with a high incidence of mild-to-moderate ADRs, but serious ADRs are extremely rare. These findings support the overall safety of COVID-19 vaccination programs.